Peak6 Investments LLC Bluebird Bio, Inc. Transaction History

Peak6 Investments LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$2.94 - $5.23 $29,400 - $52,300	10,000 New	10,000 $41,000
Q3 2021 Nov 12, 2021	SELL	$11.24 - $21.0 $251,067 - $469,077	-22,337 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$18.04 - $22.09 $93,266 - $114,205	5,170 Added 30.12%	22,337 $714,000
Q1 2021 May 14, 2021	BUY	$16.59 - $33.89 $190,287 - $388,718	11,470 Added 201.33%	17,167 $518,000
Q3 2020 Nov 13, 2020	SELL	$34.44 - $43.75 $275,623 - $350,131	-8,003 Reduced 58.42%	5,697 $199,000
Q2 2020 Aug 14, 2020	SELL	$27.12 - $45.97 $1.09 Million - $1.85 Million	-40,159 Reduced 74.56%	13,700 $836,000
Q1 2020 May 14, 2020	BUY	$26.16 - $63.5 $814,125 - $1.98 Million	31,121 Added 136.87%	53,859 $2.48 Million
Q4 2019 Feb 13, 2020	BUY	$46.96 - $61.67 $738,821 - $970,254	15,733 Added 224.6%	22,738 $2 Million
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $303,132 - $420,524	3,997 Added 132.88%	7,005 $891,000
Q1 2019 May 15, 2019	SELL	$64.44 - $104.11 $130,748 - $211,239	-2,029 Reduced 40.28%	3,008 $473,000
Q4 2018 Feb 13, 2019	BUY	$59.1 - $93.26 $297,686 - $469,750	5,037 New	5,037 $500,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Peak6 Investments LLC with notifications on news.